GEN Exclusives

More »

GEN News Highlights

More »
Jun 29, 2010

NIAID Commissions TRI and Icon for Clinical Support Services with $19M

  • Technical Resources International (TRI) and its subcontractor Icon Clinical Research have received the Clinical Research Operations and Management Support (CROMS) contract by the NIAID. An initial award of $19 million was received, and the contract has a potential total value of up to $171 million over seven years.

    Under the CROMS contract, TRI and Icon will provide NIAID's Division of Microbiology and Infectious Diseases (DMID) with support for protocol development, clinical-site monitoring, training, pharmacovigilance, the CROMS information data system, and quality management.

    DMID supports extramural research to control and prevent diseases caused by human infectious agents except HIV. A fundamental component of DMID's endeavors is the assessment of new and enhanced vaccine and therapeutic candidates in clinical trials and clinical studies.

    TRI is a full-service contract research organization with expertise in clinical trial management, regulatory affairs, medical writing, safety and pharmacovigilance, quality assurance, information technology, and communications. Icon provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in the strategic development, management, and analysis of programs that support clinical development. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?